DOCSLIB.ORG

What's New in Viral Hepatitis – Including EASL Coverage

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What's New in Viral Hepatitis – Including EASL Coverage TRANSPLANTATIONSZENTRUM What’s new in viral hepatitis – including EASL coverage Thomas Berg Clinic and Policlinic for Gastroenterology, Hepatology, Infectiology and Pneumology University Clinic Leipzig © Universitätsklinikum Leipzig What‘s new in viral hepatitis • News in HCV infection – Real-world experience with DAAs, a special emphasis on HCV type 3 – Resistance still an issue? – How to treat HCV-induced HCC and DAA-associated HCC risk – Long-term HCC risk and surveillance strategies after cure • News in HBV infection – Differences between ETV vs TDF – Cure strategies with current regimens – timing matters? – A finite approach to cure? – The race for cure in HBV – new agents in development Real World VEL/SOF Integrated analysis of 12 clinical practice cohorts n=5.541 Patients, 73% caucasian, 21% cirrhosis Mangia A et al., EASL 2019; GS-03 Real World VEL/SOF Integrated analysis of 12 clinical practice cohorts Mangia A et al., EASL 2019; GS-03 Glecaprevir/Pibrentasvir (G/P) – Italian „real-world“ effectiveness N=738 (89%) were treated for only 8 weeks D'Ambrosio R et al. J Hepatol. 2019;000 70: 379 DAA effectiveness GT3 HCV infection in England: high response rates regardless of degree of fibrosis, but RBV improves response in cirrhosis Regimen n SVR12, % P value Comparison 1 (SVR12 in GT 3 patients with moderate fibrosis) GLE/PIB (8 weeks) 92 96.6 0.793 SOF/VEL (12 weeks) 214 97.1 Comparison 2 (SVR12 in GT 3 patients with compensated cirrhosis) Comparator SOF/VEL + RBV (12 weeks) 196 98.0 regimen SOF/VEL 218 91.6 0.005* SOF + DCV + RBV 868 92.2 0.002* GLE/PIB (12 weeks) 167 96.4 NS† *vs SOF/VEL + RBV (12 weeks); †vs all other regimens. Drysdale K, et al. ILC 2019; LB-08 How to best treat HCV type 3 with cirrhosis? The role of ribavirin in the treatment of HCV type 3 with cirrhosis: A randomized trial Esteban R et al. Gastroenterology 2018;155:1120 000 The importance of baseline resistance (RAS) Esteban R et al. Gastroenterology 2018;155:1120 000 Pre-therapeutic assessment – HCV genotype and resistance However, … EASL CPG J Hepatol 2018, EASL homepage Rare HCV types in the WHO African region – Impact on treatment response? Childs K et al. EASL 2019; PS-181; J Hepatol 2019, epub Rare HCV types in the WHO African region Childs K et al. EASL 2019; PS-181; J Hepatol 2019, epub Rare HCV types in the WHO African region – Impact on treatment response? Childs K et al. EASL 2019; PS-181; J Hepatol 2019, epub Suboptimal SVR rates in African patients with atypical HCV subtypes 1: implications for global elimination of Hepatitis C? SOF/LDV, PrOD, GZR/EBR Childs K et al. EASL 2019; PS-181; J Hepatol 2019, epub Re-Treatment for patients who failed a DAA-based regimen SOF/VEL/VOX – Rescue treatment of choice (EASL CPG) Foster GR et al. Hepatology 2016; 64 (Suppl) Abstract (AASLD 2016) Real-world experience: 2nd line treatment for DAA failures Voxilaprevir/Velpatasvir/Sofosbuvir (VOX/VEL/SOF) TRIO USA Scotland Navigatore French ATU German DHC-R N=173 (N=12) (N=179) (N=46) (N=110) + Ribavirin 4% 0% 22% 20% 4% GT1 131 5 103 15 71 GT2 4 18 4 GT3 30 7 42 18 34 GT4-5 6 16 9 5 preTx V/S,G/E,3D, NS5A+SOF, SOF+PI, SOF+NS5A, SOF+PI, SOF+NS5A, SOF+X PI+NS5A3D, SOF+NS5A, 2D/3D, PI+NS5A 3D, PI+NS5A PI+NS5A, 3D Cirrhosis 43% 31% 45% 100% 27% Non-SVR n=2 n=1 n=4 n=2 n=0 Bacon et al., THU-116; Boyle et al., THU-121; Hezode et al., THU-142; Vermehren et al., THU-188 Characteristics of patients with relapse after SOF/VEL/VOX triple rescue treatment Sarrazin C et al. J Hepatol 2018 Aug 0008 [Epub] Resistance-guided retreatment of HCV patients failing NS5A inhibitors in real world • How to use resistance data in order to individualize re-treatment of DAA failure in countries with limited access to new DAA combinations Pérés AB et al. J Hepatol 2019; epub High efficacy of Resistance-guided retreatment of HCV patients failing NS5A inhibitors in real world Failure of Sofosbuvir Ledipasvir ± Ribavirin Pérés AB et al. J Hepatol 2019; epub High efficacy of Resistance-guided retreatment of HCV patients failing NS5A inhibitors in real world • The study provides evidence on how to use resistance data in order to achieve SVR rates of 90% in countries with limited access to new DAA combinations • If no NS5A RASs is found: SOF+NS5A inhibitor + RBV • If HCV type 3 and only Y93H: SOF+Velpatasvir + RBV for 24 weeks • If both NS5A and NS3 RASs: retreat with a SOF-based three-drug regimen + RBV Pérés AB et al. J Hepatol 2019; epub How to best manage patients with HCV-induced HCC? • Treat the tumor first? • Risk of HCC recurrence after DAA? SVR rates to DAA therapy in patients with chronic hepatitis C and HCC A systematic review and meta-analysis Ji F et al. J Hepatol 2019; 71: 473 Incidence of HCC in HCV-associated cirrhosis according to different treatment strategies Llovet JM and Villanueva A. Nat Rev Gastroenterol Hepatol 2016 HCC incidence – DAA- versus IFNa-based treatment Nahon P et al. Gastroenterology 2018 Jul 18 [Epub] HCC incidence – DAA- versus IFNa-based treatment weighed according to the disease severity Nahon P et al. Gastroenterology 2018 Jul 18 [Epub] 000 HCC risk after DAA treatment – post hoc image analysis (water-only DIXON MRI) Scott RA et al. Gastroenterology 2018; 154: 1846 Time association between hepatitis C therapy and HCC emergence in cirrhosis: Relevance of non-characterized nodules Marino Z et al. J Hepatol 2019; 70: 874 DAAs after successful treatment of early HCC (BCLC 0/A) improve survival in HCV-cirrhotic patients Cabibbo G et al. J Hepatol 2019; 71: 265 DAAs after successful treatment of early HCC (BCLC 0/A) improve survival in HCV-cirrhotic patients • The improvement in survival seems to be caused by a reduction in hepatic decompensation • DAAs did not impact on HCC recurrence Cabibbo G et al. J Hepatol 2019; 71: 265 Factors influencing the 5-year survival in curatively treated HCC Cabibbo et al, J Hepatol. 2017;67:65-71 No event within 1 year after complete Early HCC recurrence as first event radiological response Early hepatic decompensation as first event AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review 1. The presence of active HCC is associated with a small but statistically significant decrease in sustained virologic response with DAA therapy 2. Patients with HCC who are eligible for potentially curative therapy with liver resection or ablation should defer DAA therapy until after HCC treatment is completed. 3. There are insufficient data evaluating benefits and cost-effectiveness of DAA therapy in patients with active intermediate or advanced HCC. Decisions regarding DAA treatment in these patients should be considered in light of HCC tumor burden, degree of liver dysfunction, life expectancy, and patient preferences. Singal AG et al. AGA Clinical Practice Update. Gastroenterology 2019; 156: 2149 AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review 4. There are no conclusive data that DAA therapy is associated with increased or decreased risk, differential time to recurrence, or aggressiveness of recurrent HCC in patients with complete response to HCC therapy. 5. DAA therapy should not be withheld from patients with complete response to HCC therapy; however, DAA therapy can be deferred 4–6 months to confirm response to HCC therapy. Singal AG et al. AGA Clinical Practice Update. Gastroenterology 2019; 156: 2149 Post-treatment follow-up of patients who achieve SVR HCC risk and SVR SVR and HCC risk HCC risk after SVR – importance of cirrhosis Janjua NZ et al J Hepatol 2017; 66: 504 HCV-induced epigenetic changes associated with HCC risk persist after SVR Hamdane N and Jühling F et al. Gastroenterology 2019;156:2313–2329 Post-treatment follow-up of patients who achieve SVR EASL CPG J Hepatol 2018, EASL homepage HCC risk after SVR – the need for individualized prognostic models HCC incidence according to treatment response and individual risk factors Calvaruso V et al. Gastroenterology 2018;155:411–421 000 Individualized HCC risk prediction Ioannou GN et al. J Hepatol. 2018; 69:000 1088 Individualized HCC risk prediction www.hccrisk.com Ioannou GN et al. J Hepatol. 2018; 69:000 1088 Hepatitis B virus (HBV) - Infection Entecavir or Tenofovir When it comes to HCC prevention – are all HBV antivirals the same? Are there differences between TDF and ETV regarding HCC risk? J Choi et al., JAMA Oncol. 2019 Jan 1;5(1):30-36 Are there differences between TDF and ETV regarding HCC risk? Kim et al. J Hepatol 2019; Apr 436 epub Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B • 29,350 CHB patients (mean age 52.9 ± 13.2 years; 63.7% male) • 1,309 (4.5%) and 28,041 (95.5%) first received TDF and ETV, respectively • At a median 3.6 years FU, 8 (0.6%) TDF and 1,386 (4.9%) ETV-treated patients developed HCC HCC risk analysis Univariate analysis† Multivariable analysis† Parameters SHR 95% CI Adjusted SHR 95% CI ETV TDF vs ETV 0.15 0.07–0.29 0.32 0.16–0.65 Age 1.06 1.06–1.06 1.05 1.04–1.05 Male sex 2.17 1.90–2.47 2.42 2.11–2.76 Cirrhosis 5.73 5.16–6.36 2.30 2.01–2.64 Platelet* 0.35 0.31–0.40 0.54 0.49–0.60 Albumin 0.91 0.91–0.92 0.97 0.97–0.98 TDF ALT* 0.81 0.77–0.84 0.87 0.83–0.91 Total bilirubin* 1.48 1.41–1.56 – – HBeAg+‡ 0.82 0.73–0.93 1.44 1.26–1.65 TCF Yip et al., ILC 2019; LB-03 Definition of HBV Cure when anti-HBc titers go to zero ) SERUML +1.0 Follow-up m Therapy c/ 0.0 0 1 g o HBsAg (l e Partial Cure Anti-HBc n -1.0 aseli b m -2.0 +/- Anti-HBsAb o r f e Functional Cure ng a -3.0 h c HBV DNA -4.0 Sterilizing Cure HBV DNA HBV Time Complete Cure LIVER cccDNA X Lok et al.
Load more

Recommended publications
  • Hepatitis B and Hepatitis D Luis S
    Hepatitis B and Hepatitis D Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC June 2020 Hepatitis B Hepatitis B • 42 nm, partially double-stranded circular DNA virus. • 250 million carriers world-wide; – causes 500000 to 1 million deaths a year (686,000 in 2013) • 1.25 million carriers in USA.(0.5 %); – > 8% in Alaskan Eskimos. • Represents 5-10% of liver transplants worldwide. • New infections: decreasing in frequency – 260,000/y in 1980’s; – now 73,000/y • Greatest decline among children & adolescents (vaccine effect). Hepatitis B • Highest rate of disease in 20 to 49 year-olds • 20-30% of chronically infected americans acquired infection in childhood. • High prevalence in: – Asian-Pacific with 5-15% HBsAg(+) – Eastern European immigrants • Transmission: – In USA predominantly sexual and percutaneous during adult age. – In Alaska predominantly perinatal. Epidemiology and public health burden1 • Worldwide ≈250 million chronic HBsAg carriers2,3 • 686,000 deaths from HBV-related liver disease and HCC in 20134 HBsAg prevalence, adults (19−49 years), 20053 <2% Decreasing prevalence 2−4% in some endemic countries, e.g. Taiwan7 5−7% Possible reasons: ≥8% • Improved Not applicable socioeconomic status • Vaccination • Effective treatments Increasing prevalence in some European countries:5,6 • Migration from high endemic countries 1. EASL CPG HBV. J Hepatol 2017;67:370–98; 2. Schweitzer A, et al. Lancet 2015;386:1546–55; 3. Ott JJ, et al. Vaccine 2012;30:2212–9; 4. GBD 2013 Mortality and Causes of Death Collaborators. Lancet 2015;385:117–71; 5. Coppola N, et al.
    [Show full text]
  • New Approaches to the Treatment of Chronic Hepatitis B
    Journal of Clinical Medicine Review New Approaches to the Treatment of Chronic Hepatitis B Alexandra Alexopoulou 1,*, Larisa Vasilieva 1 and Peter Karayiannis 2 1 Department of Medicine, Medical School, National & Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece; [email protected] 2 Department of Basic and Clinical Sciences, Medical School, University of Nicosia, Engomi, CY-1700 Nicosia, Cyprus; [email protected] * Correspondence: [email protected]; Tel.: +30-2132-088-178; Fax: +30-2107-706-871 Received: 3 September 2020; Accepted: 28 September 2020; Published: 1 October 2020 Abstract: The currently recommended treatment for chronic hepatitis B virus (HBV) infection achieves only viral suppression whilst on therapy, but rarely hepatitis B surface antigen (HBsAg) loss. The ultimate therapeutic endpoint is the combination of HBsAg loss, inhibition of new hepatocyte infection, elimination of the covalently closed circular DNA (cccDNA) pool, and restoration of immune function in order to achieve virus control. This review concentrates on new antiviral drugs that target different stages of the HBV life cycle (direct acting antivirals) and others that enhance both innate and adaptive immunity against HBV (immunotherapy). Drugs that block HBV hepatocyte entry, compounds that silence or deplete the cccDNA pool, others that affect core assembly, agents that degrade RNase-H, interfering RNA molecules, and nucleic acid polymers are likely interventions in the viral life cycle. In the immunotherapy category, molecules that activate the innate immune response such as Toll-like-receptors, Retinoic acid Inducible Gene-1 (RIG-1) and stimulator of interferon genes (STING) agonists or checkpoint inhibitors, and modulation of the adaptive immunity by therapeutic vaccines, vector-based vaccines, or adoptive transfer of genetically-engineered T cells aim towards the restoration of T cell function.
    [Show full text]
  • Gilead to Acquire MYR Pharmaceuticals
    Gilead to Acquire MYR Pharmaceuticals December 9, 2020 Forward-Looking Statements This presentation includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, MYR Pharmaceuticals and the acquisition of MYR Pharmaceuticals by Gilead that are subject to risks, uncertainties and other factors, including Gilead’s ability to successfully execute its corporate strategy in its currently anticipated timelines; Gilead’s ability to make progress on any of its long-term ambitions laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its programs; the ability of the parties to complete the transaction in a timely manner or at all; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; uncertainties relating to the timing or outcome of any filings and approvals relating to the transaction; difficulties or unanticipated expenses in connection with integrating the companies, including the effects of the transaction on relationships with employees, other business partners or governmental entities; the risk that Gilead may not realize the expected benefits of this transaction; the ability of Gilead to advance MYR Pharmaceuticals’ product pipeline and successfully commercialize Hepcludex®; the ability of the parties to initiate and complete clinical trials involving Hepcludex in the currently anticipated timelines or at all; the possibility of unfavorable results from one or more of such trials involving Hepcludex; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that the U.S.
    [Show full text]
  • Hepcludex (Bulevirtide) Treatment of Hepatitis Delta Virus Infection EU/3/15/1500 Sponsor: MYR Gmbh
    31 July 2020 EMADOC-1700519818-471852 Committee for Orphan Medicinal Products Orphan Maintenance Assessment Report Hepcludex (bulevirtide) Treatment of hepatitis delta virus infection EU/3/15/1500 Sponsor: MYR GmbH Note Assessment report as adopted by the COMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Product and administrative information .................................................. 3 2. Grounds for the COMP opinion ................................................................. 4 3. Review of criteria for orphan designation at the time of marketing authorisation ............................................................................................... 4 Article 3(1)(a) of Regulation (EC) No 141/2000 .............................................................. 4 Article 3(1)(b) of Regulation (EC) No 141/2000 .............................................................. 6 4. COMP position adopted on 29 May 2020 .................................................. 6 31 July 2020 Page 2/6 1. Product and administrative information Product Active substances at the time of orphan Synthetic 47-amino acid N-myristoylated
    [Show full text]
  • First Real-Life Experiences with Bulevirtide for the Treatment of C
    First real-life experiences with bulevirtide for the treatment of C. ZÖLLNER¹, K. LUTZ¹, M. DEMIR¹, F. TACKE¹ hepatitis delta – data from a 1 Charité - University Medicine Berlin, Department of Hepatology & Gastroenterology, Campus tertiary reference centre in Virchow Klinikum and Charité Campus Mitte Germany Scan to download the Background and Aims poster 1 3 Results Hepatitis B/D coinfection is associated with rapid progression to severe liver disease Patient characteristics are summarized in table 1. The majority of patients were male (88%) and and hepatocellular carcinoma (1) and poses a relevant public health challenge in mean age was 49 years (+/- 7 SD). Three patients were cirrhotic. One patient dropped out shortly numerous countries (2-5). Effective drug therapy options for chronic hepatitis D (CHD) after inclusion because of a newly diagnosed hepatocellular carcinoma (HCC), and seven are still needed. Until 2020 interferon alpha was the only treatment option for HDV patients completed at least 16 weeks of therapy. All patients were under concomitant therapy infection. With serious side effects and a limited efficacy of about thirty percent, it with nucleoside/nucleotide analogues. None had a concomitant interferon treatment, mostly due to remains an ineffective option for a majority of patients (6-9). patients’ reticence or contraindications. A majority of patients had already completed at least one In July 2020, bulevirtide (2mg/day) was approved in the European Union for the course of interferon therapy in the past. treatment of CHD. The drug blocks the bile salt transporter NTCP, which is also the entry receptor for Hepatitis B and D viruses (10, 11).
    [Show full text]
  • Hepatitis D Virus in 2021: Virology, Immunology and New Treatment
    Recent advances in clinical practice Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult- to- treat Gut: first published as 10.1136/gutjnl-2020-323888 on 8 June 2021. Downloaded from disease Stephan Urban,1,2 Christoph Neumann- Haefelin ,3 Pietro Lampertico 4,5 1Department of Infectious ABSTRACT Diseases, Molecular Virology, Approximately 5% of individuals infected with hepatitis Key messages University Hospital Heidelberg, Heidelberg, Germany B virus (HBV) are coinfected with hepatitis D virus (HDV). 2 At least 12 million individuals infected with German Center for Infection Chronic HBV/HDV coinfection is associated with an ► Research (DZIF) - Heidelberg unfavourable outcome, with many patients developing hepatitis B virus (HBV) are coinfected with Partner Site, Heidelberg, liver cirrhosis, liver failure and eventually hepatocellular hepatitis D virus (HDV) and have a high risk Germany to develop liver cirrhosis and hepatocellular 3 carcinoma within 5–10 years. The identification of the Department of Medicine II, carcinoma within a few years. Freiburg University Medical HBV/HDV receptor and the development of novel in vitro Center, Faculty of Medicine, and animal infection models allowed a more detailed ► Until 2020, there was no specific treatment University of Freiburg, Freiburg, study of the HDV life cycle in recent years, facilitating option for the large majority of these patients; Germany off- label use of pegylated interferon-α 4 the development of specific antiviral drugs. The Division of Gastroenterology (pegIFNα) displays only approx. twenty per and Hepatology, Fondazione characterisation of HDV-specific CD4+ and CD8+T cell cent off- therapy virological response rates and IRCCS Ca’ Granda Ospedale epitopes in untreated and treated patients also permitted Maggiore Policlinico, Milan, Italy a more precise understanding of HDV immunobiology is contraindicated in many patients.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • In Vivo Models of HDV Infection: Is Humanizing NTCP Enough?
    viruses Review In Vivo Models of HDV Infection: Is Humanizing NTCP Enough? Katja Giersch 1,* and Maura Dandri 1,2,* 1 Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 2 German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Germany * Correspondence: [email protected] (K.G.); [email protected] (M.D.) Abstract: The discovery of sodium taurocholate co-transporting polypeptide (NTCP) as a hepatitis B (HBV) and delta virus (HDV) entry receptor has encouraged the development of new animal models of infection. This review provides an overview of the different in vivo models that are currently available to study HDV either in the absence or presence of HBV. By presenting new advances and remaining drawbacks, we will discuss human host factors which, in addition to NTCP, need to be investigated or identified to enable a persistent HDV infection in murine hepatocytes. Detailed knowledge on species-specific factors involved in HDV persistence also shall contribute to the development of therapeutic strategies. Keywords: mouse model; infection; hepatitis delta; NTCP; human liver chimeric mice; HDV persis- tence; HDV replication; host restriction factors; innate immunity; chronic viral hepatitis 1. Hepatitis Delta Virus Citation: Giersch, K.; Dandri, M. The hepatitis delta virus (HDV) was discovered in Italy in 1977 [1] and still causes at In Vivo Models of HDV Infection: least 15–20 million chronic infections worldwide [2]. Recent metanalyses estimated the Is Humanizing NTCP Enough? HDV infection prevalence even at 62–72 million [2–4]. HDV is not only the smallest RNA Viruses 2021, 13, 588. https:// pathogen known to interact with a human host, but it is also a satellite virus which needs doi.org/10.3390/v13040588 the expression of the envelope proteins of the hepatitis B virus (HBV) for the release of HDV particles and propagation among hepatocytes.
    [Show full text]
  • Download Press
    ILC 2019 TM MEDIA KIT THE INTERNATIONAL LIVER CONGRESS™ VIENNA, AUSTRIA | 10-14 APRIL, 2019 1 CONTENTS About EASL 3 About ILC 4 Press Conference Programme 5 EASL Press Releases: Wednesday, 10 April 6 EASL Press Releases: Thursday, 11 April 8 EASL Press Releases: Friday, 12 April 20 EASL Press Releases: Saturday, 13 April 32 Media Release 55 (Coalition launches Global Scientific Strategy to Cure Hepatitis B) Background Information 58 2 ABOUT EASL The European Association for the Welcome Message Study of the Liver (EASL) is a not-for- From The EASL profit medical association dedicated to Secretary General: pursuing excellence in liver research, Prof. Tom clinical practice of liver disorders, and Hemming Karlsen in providing education to all those interested in hepatology. Whilst the roots of the association were founded in Europe in 1966, EASL On behalf of EASL, I welcome continues to engage globally with all you to the International Liver stakeholders in the liver field wherever CongressTM (ILC) 2019 and they are based. Our aim is to spread thank you for your support of Europe’s knowledge, expertise and best practice as leading organisation dedicated to well as the latest scientific breakthroughs in advancing the scientific, medical and hepatology and the International Liver public understanding of the liver. Congress™ is our annual platform for achieving this aim. Since its foundation in 1966, EASL has evolved into a driving force by supporting EASL’s mission is to be the Home of the education of healthcare professionals, Hepatology so that all who are involved promoting research in the field of liver with treating liver disease can realise their disease and fostering policy changes to full potential to cure and prevent it.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Recent Advances in Hepatitis B Treatment
    pharmaceuticals Review Recent Advances in Hepatitis B Treatment Georgia-Myrto Prifti 1, Dimitrios Moianos 1 , Erofili Giannakopoulou 1, Vasiliki Pardali 1, John E. Tavis 2 and Grigoris Zoidis 1,* 1 Department of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece; [email protected] (G.-M.P.); [email protected] (D.M.); [email protected] (E.G.); [email protected] (V.P.) 2 Molecular Microbiology and Immunology, Saint Louis University, Saint Louis, MO 63104, USA; [email protected] * Correspondence: [email protected]; Tel.: +30-210-7274809 Abstract: Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antivi- ral agents, pegylated interferon and nucleos(t)ide analogues, have major drawbacks and fail to completely eradicate the virus from infected cells. Thus, achieving a “functional cure” of the in- fection remains a real challenge. Recent findings concerning the viral replication cycle have led to development of novel therapeutic approaches including viral entry inhibitors, epigenetic control of cccDNA, immune modulators, RNA interference techniques, ribonuclease H inhibitors, and capsid assembly modulators. Promising preclinical results have been obtained, and the leading molecules under development have entered clinical evaluation. This review summarizes the key steps of the HBV life cycle, examines the currently approved anti-HBV drugs, and analyzes novel HBV treatment regimens. Citation: Prifti, G.-M.; Moianos, D.; Keywords: hepatitis B; hepatitis B virus; HBV; antiviral agents; HBV inhibitors; cccDNA; HBV life Giannakopoulou, E.; Pardali, V.; Tavis, cycle; HBV treatment; nucleoside analogues; antiviral therapy J.E.; Zoidis, G.
    [Show full text]
  • Viral Hepatitis About These Slides
    Best of ILC 2019 Viral hepatitis About these slides • These slides provide highlights of new data presented at the International Liver Congress 2019 • Please feel free to use, adapt, and share these slides for your own personal use; however, please acknowledge EASL as the source • Definitions of all abbreviations shown in these slides, and a full copy of the original abstract text, are provided within the slide notes • Submitted abstracts are included in the slide notes, but data may not be identical to the final presented data shown on the slides These slides are intended for use as an educational resource and should not be used to make patient management decisions. All information included should be verified before treating patients or using any therapies described in these materials Contents 1. Viral hepatitis C: Therapy and resistance Global real-world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C GS-03 patients GS-07 Glecaprevir/pibrentasvir: Real-world safety, effectiveness, and patient-reported outcomes in the German Hepatitis C-Registry DAA effectiveness in England: high response rates in GT 3 HCV infection regardless of degree of fibrosis, but RBV improves LB-08 response in cirrhosis The hepatitis C cascade of care and treatment outcomes among people who inject drugs in a Norwegian low-threshold setting: PS-068 A real-life experience NS5A resistance profile of GT 1b virological failures that impacts outcome of re-treatment with GLE/PIB: PS-180 A nationwide real-world study PS-181 Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes: Implications for global elimination Click here to skip to this section Contents 2.
    [Show full text]